| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) |
| 08 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 3, 2026, Beam Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of w... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half o... |
| 05 Mar 2026 |
8-K: Termination of a Material Definitive Agreement
On March 2, 2026 (the “Termination Date”), Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) mutually terminated the License Agreement by and between the Company and Bio Palette dated March 27, 2019 (the “L... |
| 24 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) |
| 12 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
CERTAIN IMMATERIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(a)(5), (a)(6) and (b)(10)(iv). |
| 05 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 31, 2026, Carole Ho provided Beam Therapeutics Inc. (the “Company”) with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026. Dr. Ho’s decision to resign did not result from ... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition |
| 11 Dec 2025 |
8-K: Completion of Acquisition or Disposition of Assets
On December 8, 2025, Bristol-Myers Squibb Company (“BMS”) completed its previously announced acquisition of Orbital Therapeutics, Inc. (“Orbital”) pursuant to an Agreement and Plan of Merger dated October 10, 2025 between Orbital and BMS... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026 |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) |
| 03 Jul 2025 |
8-K: Unregistered Sales of Equity Securities
On July 1, 2025, Beam Therapeutics Inc. (the “Company”) entered into an Agreement and Plan of Merger pursuant to which it acquired an early-stage life sciences company (the “Agreement”). As consideration for the acquisition, the Company ... |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2025, Beam Therapeutics Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of w... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program |
| 10 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Pre-Funded Warrants to Purchase 1,404,988 Shares of Common Stock |
| 10 Mar 2025 |
8-K: Regulation FD Disclosure; Other Events
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition
Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
PRECISION GENETIC MEDICINES THROUGH BASE EDITING NASDAQ: BEAM January 2025 |
| 09 Dec 2024 |
8-K: Regulation FD Disclosure; Other Events
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual ... |
Loading...